At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...

In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US ...

Biologics have revolutionized the medical landscape with their targeted mechanisms of action and potential for treating a wide array of indications. As the global population grapples with an ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

Japan-based pharmaceutical company Kyowa said it is planning to buy land in the Helix Innovation Park in Sanford, North Carolina to build a manufacturing facility to support the production and supply ...

Industry will see mid-teens grams/L of product within five years but downstream processes are the big ‘virgin territory’ for further productivity gains, says Avantor’s Ger Brophy. In the aftermath of ...

Resilience, the contract development and manufacturing organization (CDMO) in all-but-name that launched in November 2019, has laid plans to expand fill and finish facilities in Cincinnati, Ohio and ...

Indian pharmaceutical company Intas Pharmaceuticals signed a deal to acquire Udenyca, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications. Accord ...

Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

Articles In Color Color reprints are printed on 70# enamel paper and can be reproduced in color or in black and white. Color articles reprinted in black and white will be charged black and white ...

Cell line development involves the screening of thousands of clones in an effort to find the few optimal clones that are stable, grow as expected, and produce high yields of the bioproduct. The time ...

As of its 2023 guidance on combination and boundary products, the Australian Therapeutic Goods Administration (TGA) has provided context around key regulated product categories: Combination products ...